Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anteris Technologies Global Corp. ( (AVR) ) just unveiled an update.
On May 11, 2026 in the U.S. (May 12, 2026 in Australia), Anteris Technologies Global Corp. appointed Susan Knight and returning director Stephen Denaro to its Board of Directors, assigning Knight as a Class I Director through the 2028 annual meeting and Denaro as a Class II Director through the 2026 annual meeting. Knight, a veteran finance executive and former board chair at medical device provider Surmodics, Inc., will also join the Audit and Risk Committee, while both new non‑employee directors will receive cash retainers, equity-based compensation in line with the company’s director policy, and indemnification agreements that strengthen their legal protection and signal an effort to deepen governance, audit oversight, and experienced financial leadership as the firm advances its strategic priorities.
The company detailed that Knight’s initial restricted stock unit grant will vest over three years subject to ongoing board service and stockholder approval, and both directors will be eligible for prorated annual equity awards depending on their tenure. Denaro, who already serves as company secretary to several Australian subsidiaries for a fixed annual fee, brings deep knowledge of Anteris’s strategy, while the newly executed Delaware-law indemnification agreements underscore a standard but important governance practice aimed at supporting board recruitment, enhancing director confidence, and reinforcing stability for shareholders and other stakeholders.
The most recent analyst rating on (AVR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Spark’s Take on AVR Stock
According to Spark, TipRanks’ AI Analyst, AVR is a Neutral.
The score is primarily held down by very weak financial performance (declining revenue, large recurring losses, negative equity, and heavy cash burn). Technicals are neutral and provide limited support, while valuation is constrained by losses and lack of dividend. A positive operational event (new facility lease with abatements) helps modestly but does not offset the elevated financing risk.
To see Spark’s full report on AVR stock, click here.
More about Anteris Technologies Global Corp.
Anteris Technologies Global Corp. operates in the medical technology sector, with a focus on advanced medical device solutions. The company is listed on the Australian Securities Exchange and maintains a global corporate structure that includes Australian subsidiary entities, reflecting its international operating footprint and governance framework.
Average Trading Volume: 859,940
Technical Sentiment Signal: Buy
Current Market Cap: $651.5M
Find detailed analytics on AVR stock on TipRanks’ Stock Analysis page.